CN101623293A - Medical composition for injection - Google Patents
Medical composition for injection Download PDFInfo
- Publication number
- CN101623293A CN101623293A CN200910091026A CN200910091026A CN101623293A CN 101623293 A CN101623293 A CN 101623293A CN 200910091026 A CN200910091026 A CN 200910091026A CN 200910091026 A CN200910091026 A CN 200910091026A CN 101623293 A CN101623293 A CN 101623293A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- regulator
- riboflavin
- solution
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medical composition for injection, which is characterized by comprising the following components by weight part: 5-20 parts of vitamin B1, 1-10 parts of riboflavin sodium phosphate (metered by riboflavin), 100-300 parts of vitamin C, 100-500 parts of excipient, 0.1-1 part of complexing agent and a pH regulating agent. Compared with a vitamin C injection on the market, the medical composition has low content of related substances and high content of effective constituents; and proved by high-temperature, high-humidity and strong-light tests, the medical composition has better stability.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of composite vitamin for injection C pharmaceutical composition.
Background technology
So-called " nutritional supplementation ", comprise the necessary nutrients of five big healths such as saccharide, protein, fat, vitamin, mineral, these materials are walked around liver and are directly entered the body circulation, its assimilation ratio may be slightly poorer than through gastrointestinal tract and ingest, but also can satisfy the needs of keeping nutrition provides nutrient can reduce gastral secretion and wriggling through parenteral, make digestive tract be in resting state, help disease recovery or healing.Though can not reach healing fully voluntarily sometimes, behind positive nutritional support, the whole body situation has greatly improved, and the chance that further treatment is succeedd increases greatly, and mortality rate falls sharply.When short bowel syndrome, can play the effect of keeping nutrition, until till the abundant compensatory adaptation of intestinal.Since phase late 1960s, total intravenous nutrition was employed, this technology had obtained significant curative effect very soon and has obtained promoting, and now has been widely used in clinical.Owing to disease or operation factor cause can't taking food more than seven days, or food-intake can't keep health required and accept again nearly one the step treatment, or operation, and the patient of short intestinal disease needs vein to supplement the nutrients, comprise that gastrointestinal absorption dysfunction patient is (as extensive small bowel resection postoperative, the small intestinal illness, radiation enteritis, serious diarrhoea, obstinate vomit), heavy dose of radiotherapy, chemotherapy or accept the bone marrow transplant patient, middle severe acute pancreatitis, severe malnutrition companion gastrointestinal dysfunction, serious catabolism state, with or without malnutrition and the patient that gastrointestinal tract can not obtain in 5-7 days, all need give total intravenous nutrition, evident in efficacy.In addition, big operation wound and plyability wound, moderate stress, intestinal fistula, inflammatory bowel disease, hyperemesis gravidarum or nerve refusing to eat, the moderate malnutrition that need accept major operation or intensive chemotherapy, the back of being admitted to hospital can not set up competent enteral nutrition, adhesive intestinal stalk etc. in 7-10 days and also can use total intravenous nutrition.
The compound vitamin C injection is the part of intravenous nutrition, and the supply when being used for some and can't fully absorbing vitamin by food is as wasting diseases, gravid woman, nursing women; Be used for owing to disease or operation factor cause can't taking food more than seven days or food-intake can't to keep health required and accept the treatment or the operation in a nearly step again, and the patient of short intestinal disease needs vein to supplement the nutrients, be used for improving the nutritional status of patient's whole body, prolong patient's life.Raising along with people's living standard, the total intravenous nutrition clinical practice is increasingly extensive, market potential is huge, the compound vitamin C injection is in Japan's listing several years, but vitamin C stability in aqueous solution is very poor, therefore, the medicine developer wishes to work out injectable powder or lyophilized injectable powder replaces injection, in the process of research injectable powder or lyophilized injectable powder, run into the problem of crude drug stability equally, so the research of compound vitamin C injectable powder or lyophilized powder always can't be successful.
Summary of the invention
For these reasons, our scientific research personnel has found the pharmaceutical composition of compound vitamin C injectable powder or lyophilized injectable powder supplementary material by concentrating on studies for many years, the preparation of preparation of pharmaceutical compositions, and vitamin C stability is better, its related substances is low, and product quality is more outstanding.
The present invention is achieved through the following technical solutions.
A kind of medicinal composition for injections, it is by vitamin B
1The 5-20 weight portion, riboflavin sodium phosphate (in riboflavin) 1-10 weight portion, vitamin C 100-300 weight portion, excipient 100-500 weight portion, chelating agent 0.1-1 weight portion, the pH regulator agent is formed.
Wherein preferred pharmaceutical composition is by vitamin B
110 weight portions, riboflavin sodium phosphate (in riboflavin) 5 weight portions, Catergen 00 weight portion, excipient 300 weight portions, chelating agent 0.5 weight portion, the pH regulator agent is formed.
Wherein excipient includes but not limited to one or more in mannitol, lactose, sodium chloride, glucose, glycine, meglumine, the dextran.
Wherein chelating agent include but not limited to sodium calcium edetate, disodium edetate, cyclohexanediamine four sodium acetates, N-hydroxy-ethylenediamine three acetic acid one or more.
Wherein the pH regulator agent include but not limited to sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate one or more.
The pharmaceutical preparation of above-mentioned medicinal composition for injections.
Wherein preparation is lyophilized injectable powder or injectable powder.
Wherein the preparation method of injectable powder can be prepared according to prior art, include but not limited to following preparation method: vitamin C adds the pH regulator agent after adding the dissolving of injection water, and the regulator solution pH value is to 4.0-6.0, when treating that the carbon dioxide bubble does not take place solution, add vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, the regulator solution pH value adds the active carbon of 0.01%-0.05% (weight/volume) then to 4.0-6.0, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
Wherein the preparation method of lyophilized injectable powder can be prepared according to prior art, include but not limited to following preparation method: vitamin C adds the pH regulator agent after adding the dissolving of injection water, and the regulator solution pH value is to 4.0-6.0, when treating that the carbon dioxide bubble does not take place solution, add vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, the regulator solution pH value adds the active carbon of 0.01%-0.05% (weight/volume) then to 4.0-6.0, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
1, assay
Measure according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2005).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; To contain the methanol-water (20: 80) of 0.1% sodium hexanesulfonate, 2.4% glacial acetic acid, the solution that mixing is regulated pH value to 3.5 with triethylamine is mobile phase, and flow velocity is 1.0ml/min, and the detection wavelength is 266nm.The separating degree of each component should be up to specification.
The preparation lucifuge operation of reference substance solution, get the about 50mg of vitamin B1 reference substance, the about 34mg of riboflavin sodium phosphate reference substance and the about 1.0g of vitamin C reference substance, accurate claim surely, put in the brown measuring bottle of 200ml, be dissolved in water and be diluted to scale, shake up, precision is measured 5ml, puts in the brown measuring bottle of 100ml, is diluted with water to scale, shake up, promptly get reference substance solution.This solution should face uses new system, and the configuration back is preserved in refrigerator and used in 6 hours.
The preparation lucifuge operation of need testing solution, get the content an amount of (being equivalent to vitamin C 25mg approximately) under the content uniformity item, the accurate title, decide, put in the brown measuring bottle of 100ml, with water dissolution and be diluted to scale, shake up, promptly get the need testing solution that contains VB11 2.5 μ g, riboflavin 6.25 μ g and vitamin C 0.25mg among every 1ml approximately.This solution should face uses new system, and the configuration back is preserved in refrigerator and used in 6 hours.
Algoscopy is got reference substance solution and each 10 μ l of need testing solution, injects chromatograph of liquid, and the record chromatogram is pressed external standard method with each constituent content of calculated by peak area, promptly.
2, related substance detects
Measure according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2005).
Chromatographic condition and system suitability test are filler with the amino bonded Bio-sil; With (0.02mol/L) potassium dihydrogen phosphate-acetonitrile (27: 73), regulating pH with 10% hydrochloric acid solution behind the mixing is that 5.3 solution is mobile phase, and flow velocity is 1.5ml/min, and the detection wavelength is 266nm.The separating degree of each component should be up to specification.
It is an amount of that algoscopy is got this product, adds water and make the solution that contains vitamin C 2mg among every 1ml, as need testing solution; It is an amount of that precision is measured need testing solution, and thin up is made the solution that contains vitamin C 20 μ g among every 1ml, solution in contrast.Get contrast solution 20 μ l and inject chromatograph of liquid, regulate detection sensitivity, the peak height that makes vitamin B1 composition chromatographic peak is 10% of a full scale; Get need testing solution 20 μ l again and inject chromatograph of liquid, the record chromatogram is to 6～7 times of vitamin B1 chromatographic peak retention time.
Result of the test:
Table 1 present composition formulation content and related substance
| Group | Vitamin B 1Content % | Vitamin C content % | The riboflavin phosphate sodium content | Its related substances % |
| ????％ | ||||
| Lyophilized injectable powder of the present invention | ????99.31 | ????97.06 | ????97.48 | ????0.73 |
| Injectable powder of the present invention | ????99.82 | ????97.73 | ????98.02 | ????0.79 |
3, high temperature comparative test
Get pharmaceutical composition of the present invention and place 40 ℃ of two experimental enviroments simultaneously with listing compound vitamin C injection, sampling and measuring when placing the 5th, 10 day, the result compared with zero day, and result of the test sees Table 2:
Table 2 hot test result
4, strong illumination comparative test
Get pharmaceutical composition of the present invention and listing compound vitamin C injection and place simultaneously under 4400 the illumination meter, sampling and measuring when placing the 5th, 10 day, the result with zero day relatively, measurement result sees Table 3.
Table 3 highlight test result
5, high humidity comparative test
Get pharmaceutical composition of the present invention and listing compound vitamin C injection and place the condition of RH92.5% ± 5% simultaneously, sampling and measuring when placing the 5th, 10 day, the result with zero day relatively, measurement result sees Table 4:
Table 4 high humidity result of the test
Conclusion (of pressure testing): above-mentioned comparative test shows that pharmaceutical composition of the present invention compares with listing compound vitamin C injection, and its related substances is low, the content of effective height, and by high temperature, high humidity, highlight test, pharmaceutical composition stability of the present invention is better.
6, preparation embodiment
Embodiment 1
A kind of medicinal composition for injections is by vitamin B
15g, riboflavin sodium phosphate (in riboflavin) 1g, vitamin C 100g, excipient 100g, chelating agent 0.1g, the pH regulator agent is formed in right amount.
Embodiment 2
A kind of medicinal composition for injections is by vitamin B
120g, riboflavin sodium phosphate (in riboflavin) 10g, vitamin C 300g, excipient 500g, chelating agent 1g, the pH regulator agent is formed in right amount.
Embodiment 3
A kind of medicinal composition for injections is by vitamin B
16g, riboflavin sodium phosphate (in riboflavin) 2g, vitamin C 120g, excipient 150g, chelating agent 0.15g, the pH regulator agent is formed in right amount.
Embodiment 4
A kind of medicinal composition for injections is characterized in that it is by vitamin B
16g, riboflavin sodium phosphate (in riboflavin) 3g, vitamin C 145g, excipient 275g, chelating agent 0.2g, the pH regulator agent is formed in right amount.
Embodiment 5
A kind of medicinal composition for injections is by vitamin B
17g, riboflavin sodium phosphate (in riboflavin) 4g, vitamin C 185g, excipient 210g, chelating agent 0.4g, the pH regulator agent is formed in right amount.
Embodiment 6
A kind of medicinal composition for injections, it is by being by vitamin B
110g, riboflavin sodium phosphate (in riboflavin) 5g, Catergen 00g, excipient 300g, chelating agent 0.5g, the pH regulator agent is formed in right amount.
Embodiment 7
A kind of medicinal composition for injections, it is by vitamin B
118g, riboflavin sodium phosphate (in riboflavin) 7.5g, Catergen 75g, excipient 395g, chelating agent 0.85g, the pH regulator agent is formed in right amount.
Embodiment 8
A kind of medicinal composition for injections, it is by vitamin B
119.5g, riboflavin sodium phosphate (in riboflavin) 9g, Catergen 95g, excipient 455g, chelating agent 0.95g, the pH regulator agent is formed in right amount.
Excipient includes but not limited to one or more in mannitol, lactose, sodium chloride, glucose, glycine, meglumine, the dextran among the foregoing description 1-8.
Among the foregoing description 1-8 chelating agent include but not limited to sodium calcium edetate, disodium edetate, cyclohexanediamine four sodium acetates, N-hydroxy-ethylenediamine three acetic acid one or more.
Among the foregoing description 1-8 the pH regulator agent include but not limited to sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate one or more.
The pharmaceutical preparation of medicinal composition for injections among the foregoing description 1-8.
Wherein preparation is lyophilized injectable powder or injectable powder, and the preparation method of lyophilized injectable powder can be prepared according to the method for existing document record, also can prepare according to following method:
Embodiment 9
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 4.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 4.0 adds the active carbon of 0.01% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
Embodiment 10
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 6.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 6.0 adds the active carbon of 0.05% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
Embodiment 11
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 4.5 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 4.5 adds the active carbon of 0.02% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
Embodiment 12
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 5.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 5.0 adds the active carbon of 0.03% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
Embodiment 13
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 5.5 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 5.5 adds the active carbon of 0.04% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
The preparation method of injectable powder can be prepared according to the method for existing document record, also can prepare according to following method:
Embodiment 14
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 4.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 4.0 adds the active carbon of 0.01% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
Embodiment 15
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 6.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 6.0 adds the active carbon of 0.05% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
Embodiment 16
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 4.5 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 4.5 adds the active carbon of 0.02% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
Embodiment 17
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 5.0 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 5.0 adds the active carbon of 0.03% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
Embodiment 18
After getting vitamin C and adding injection water dissolving, add the pH regulator agent, regulator solution pH value to 5.5 when treating that the carbon dioxide bubble does not take place solution, adds vitamin B
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, regulator solution pH value to 5.5 adds the active carbon of 0.04% (weight/volume) then, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
The present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Claims (9)
1, a kind of medicinal composition for injections is characterized in that it is by vitamin B
1The 5-20 weight portion, riboflavin sodium phosphate (in riboflavin) 1-10 weight portion, vitamin C 100-300 weight portion, excipient 100-500 weight portion, chelating agent 0.1-1 weight portion, the pH regulator agent is formed.
2, a kind of medicinal composition for injections according to claim 1, wherein it is by vitamin B
110 weight portions, riboflavin sodium phosphate (in riboflavin) 5 weight portions, Catergen 00 weight portion, excipient 300 weight portions, chelating agent 0.5 weight portion, the pH regulator agent is formed.
3, a kind of medicinal composition for injections according to claim 1 and 2, wherein excipient is one or more in mannitol, lactose, sodium chloride, glucose, glycine, meglumine, the dextran.
4, a kind of medicinal composition for injections according to claim 1 and 2, wherein chelating agent is one or more in sodium calcium edetate, disodium edetate, cyclohexanediamine four sodium acetates, N-hydroxy-ethylenediamine three acetic acid.
5, a kind of medicinal composition for injections according to claim 1 and 2, wherein the pH regulator agent be sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate one or more.
6, the pharmaceutical preparation of a kind of medicinal composition for injections preparation according to claim 1 and 2.
7, pharmaceutical preparation according to claim 6, wherein preparation is lyophilized injectable powder or injectable powder.
8, the preparation method of injectable powder is in the pharmaceutical preparation according to claim 7: get vitamin C and add the dissolving of injection water, add the pH regulator agent, the regulator solution pH value when treating that the carbon dioxide bubble does not take place solution, adds vitamin B to 4.0-6.0
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, the regulator solution pH value adds the active carbon of 0.01%-0.05% (weight/volume) then to 4.0-6.0, stirs, and leaves standstill decarbonization filtering, sterilization, fill, drying, promptly.
9, the preparation method of lyophilized injectable powder is in the pharmaceutical preparation according to claim 7: after getting vitamin C and adding injection water dissolving, add the pH regulator agent, the regulator solution pH value when treating that the carbon dioxide bubble does not take place solution, adds vitamin B to 4.0-6.0
1, riboflavin sodium phosphate, excipient and chelating agent, dissolving, the regulator solution pH value adds the active carbon of 0.01%-0.05% (weight/volume) then to 4.0-6.0, stirs, and leaves standstill decarbonization filtering, sterilization, fill, lyophilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910091026A CN101623293A (en) | 2009-08-20 | 2009-08-20 | Medical composition for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910091026A CN101623293A (en) | 2009-08-20 | 2009-08-20 | Medical composition for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101623293A true CN101623293A (en) | 2010-01-13 |
Family
ID=41519388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910091026A Pending CN101623293A (en) | 2009-08-20 | 2009-08-20 | Medical composition for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623293A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552294A (en) * | 2012-01-10 | 2012-07-11 | 辽宁海思科制药有限公司 | Compound vitamin (3) freeze-dried powder injection for injection and preparation method and analysis method thereof |
| CN103202844A (en) * | 2013-04-25 | 2013-07-17 | 辽宁海思科制药有限公司 | Compound vitamin (3) pharmaceutical composition for injection and preparation method thereof |
| CN103565811A (en) * | 2012-07-18 | 2014-02-12 | 河北智同医药控股集团有限公司 | Compound vitamin lyophilized preparation for injection and its preparation method |
| CN104490901A (en) * | 2014-12-30 | 2015-04-08 | 王大光 | Compound vitamin injection medical composition and preparation method thereof |
| CN104490903A (en) * | 2014-12-30 | 2015-04-08 | 王大光 | Compound vitamin injection pharmaceutical composition and preparation method thereof |
| CN104523714A (en) * | 2014-12-30 | 2015-04-22 | 李迪 | Compound vitamin injection medicine composition and preparation method |
| CN104606209A (en) * | 2014-12-30 | 2015-05-13 | 王大光 | Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition |
| CN109364082A (en) * | 2018-06-08 | 2019-02-22 | 河北爱尔海泰制药有限公司 | A kind of high stability composite vitamin for injection lyophilized preparation composition |
| CN115140361A (en) * | 2022-07-21 | 2022-10-04 | 宁波依兰雅丝护肤品有限公司 | Preparation method of aseptic preservative-free fresh-keeping of cigarette cartridge |
-
2009
- 2009-08-20 CN CN200910091026A patent/CN101623293A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552294A (en) * | 2012-01-10 | 2012-07-11 | 辽宁海思科制药有限公司 | Compound vitamin (3) freeze-dried powder injection for injection and preparation method and analysis method thereof |
| CN103565811A (en) * | 2012-07-18 | 2014-02-12 | 河北智同医药控股集团有限公司 | Compound vitamin lyophilized preparation for injection and its preparation method |
| CN103565811B (en) * | 2012-07-18 | 2014-08-20 | 河北智同医药控股集团有限公司 | Compound vitamin lyophilized preparation for injection and its preparation method |
| CN103202844A (en) * | 2013-04-25 | 2013-07-17 | 辽宁海思科制药有限公司 | Compound vitamin (3) pharmaceutical composition for injection and preparation method thereof |
| CN104490901A (en) * | 2014-12-30 | 2015-04-08 | 王大光 | Compound vitamin injection medical composition and preparation method thereof |
| CN104490903A (en) * | 2014-12-30 | 2015-04-08 | 王大光 | Compound vitamin injection pharmaceutical composition and preparation method thereof |
| CN104523714A (en) * | 2014-12-30 | 2015-04-22 | 李迪 | Compound vitamin injection medicine composition and preparation method |
| CN104606209A (en) * | 2014-12-30 | 2015-05-13 | 王大光 | Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition |
| CN104523714B (en) * | 2014-12-30 | 2017-06-27 | 李迪 | A kind of Compound vitamine injection pharmaceutical composition and preparation method |
| CN109364082A (en) * | 2018-06-08 | 2019-02-22 | 河北爱尔海泰制药有限公司 | A kind of high stability composite vitamin for injection lyophilized preparation composition |
| CN115140361A (en) * | 2022-07-21 | 2022-10-04 | 宁波依兰雅丝护肤品有限公司 | Preparation method of aseptic preservative-free fresh-keeping of cigarette cartridge |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101623293A (en) | Medical composition for injection | |
| CN106456717B (en) | Quick-acting insulin composition | |
| Yang et al. | Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation | |
| CN101366692A (en) | Stable Exenatide formulation | |
| US20070286911A1 (en) | Huperzia serrate (thunb.) trev. composition comprising compounded huperzine a and huperzine b and methods for preparing it | |
| EP3159005A1 (en) | Uric acid level lowering agent | |
| CN105395616A (en) | Injection for clearing heat, eliminating phlegm and removing toxicity | |
| CN1840177B (en) | Injection liquid of thymic peptide alpha 1 and preparation method thereof | |
| CN101623284A (en) | Medical composition of compound vitamin C injection | |
| CN103764132A (en) | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use | |
| CN104138469A (en) | Medicinal composite preparation for treating type 2 diabetes and reversing insulin resistance, and preparation method thereof | |
| CN102525963B (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| KR20180082428A (en) | Detection and treatment of growth hormone deficiency | |
| EP3574912B1 (en) | Composition for treating diabetic disease | |
| Zheng et al. | Acute effects of peritoneal dialysis solutions on appetite in non-uremic rats | |
| CN103191115A (en) | Application of pyrroloquinoline quinone (PQQ) in treatment and/or improvement of diabetic foot | |
| CN104667258A (en) | Octreotide acetate tablet and preparation method thereof | |
| CN103202844A (en) | Compound vitamin (3) pharmaceutical composition for injection and preparation method thereof | |
| CN104688676A (en) | Andrographolide concentrated liquid and medical application thereof | |
| CN101647773A (en) | Octreotide acetate injection | |
| CN116763777A (en) | Application of 17-hydro-9-dehydroandrographolide-19-sodium sulfate in preparing medicament for treating cow mastitis | |
| CN102125583A (en) | Pediatric paracetamol, cow-bezoar and chlorphenamine maleate granules and quality control method thereof | |
| CN101428020B (en) | Freeze-dried powder preparation of kuh-seng native, preparation method thereof | |
| CN107158026A (en) | Application of the low-ester pectin in preventing and treating or auxiliary treatment diabetes | |
| Taylor-Edwards et al. | Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20100113 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |